What We're Reading: Page 102
Industry reads hand-picked by our editors
Dec 19, 2022
-
Axios
Antibiotic, drug shortages highlight America’s supply chain problems — again
-
The New York Times
They Created a Drug for Susannah. What About Millions of Other Patients?
-
Fierce Pharma
After Novo’s Wegovy supply woes, rival Lilly sees shortages for Mounjaro, Trulicity
-
Reuters
Probe of Musk’s Neuralink to scrutinize long-criticized U.S animal welfare regulator
Dec 16, 2022
-
Politico
AbbVie exits the lobby
-
The New York Times
Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics?
-
The Wall Street Journal
Siddhartha Mukherjee on How Cellular Medicine Could Fight Cancer, Diabetes
Dec 15, 2022
-
Stat News
Prisons say they can’t afford to cure everyone with hepatitis C. But some are figuring out a way
-
Fierce Biotech
45 days later, BioCryst abandons another drug, citing competition
-
The Pharma Letter
Novartis to divest five eye drugs to Harrow
-
The Wall Street Journal
Why You Might Be Having Trouble Buying Children’s Flu and Cold Medicine
Dec 14, 2022
-
Fierce Biotech
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
-
MIT Technology Review
Neuroscientists have created a mood decoder that can measure depression
-
Bloomberg
Long Covid’s Effects Go Beyond Respiratory Issues
Dec 13, 2022
Dec 12, 2022
-
The Wall Street Journal
The Biotech Takeout Menu Gets Pricier
-
Axios
The growing market for weight loss drugs
-
Financial Times
Immunocore’s Bahija Jallal: ‘There was fantastic science, but without financing, we could not go anywhere’
Dec 09, 2022
-
The Wall Street Journal
Mark Cuban Has a New Job: Working at an Online Discount Pharmacy
-
Reuters
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say
-
The New York Times
The F.T.C.’s Bet on Rewriting Antitrust by Taking on Microsoft
-
MIT Technology Review
DNA that was frozen for 2 million years has been sequenced
Previous
